Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Vera Therapeutics, Inc.NASDAQ: VERA
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $60.08M rose 3.2% year over year, behind the +51.3% change in trailing-twelve-month research & development. Sequentially, it fell 30.1% from the prior quarter. Over 3 fiscal years it compounded at +45.5% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.2% toward the trailing-twelve-month pace of +51.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 215.26M USD
- Year-over-year change
- +70.6%
- 4-year CAGR
- +75.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 215.26M | +70.6% |
| FY2024 | 2024-12-31 | 126.17M | +61.3% |
| FY2023 | 2023-12-31 | 78.23M | +12.0% |
| FY2022 | 2022-12-31 | 69.84M | +210.6% |
| FY2021 | 2021-12-31 | 22.48M | — |
Research & Development vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 research & development of $261.87M is the 3rd highest of the 10 companies compared; the peer median is $128.65M.
- Its year-over-year change of +51.3% is the 4th highest of 10, against a peer median of +22.1%.
- Over three fiscal years its annual growth of +45.5% compares with a peer median of +23.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $467.76M | -32.9% | +13.3% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $346.63M | -8.7% | +56.3% | 4685.4% |
| LTM Jun 2026 | $261.87M | +51.3% | +45.5% | — | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
| LTM Jun 2026 | $175.6M | +66.9% | +70.5% | 9222.6% | |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $126.01M | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $104.71M | +22.1% | +23.1% | 28.3% | |
| LTM Jun 2026 | $91.04M | +28.3% | -25.0% | 19.6% | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| Peer median (excluding VERA) | $128.65M | +22.1% | +23.1% | 366.6% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.